Researchers assessed the real-life effect of the immunological-based decision of treatment cessation (TC) on the 3 and 6-month relapse rate following TC in bullous pemphigoid. They found that 3 and 6-month relapse rate was not significantly decreased with TC decision depending on findings of ITs (immunological tests) vs a classical clinical-based decision.

• In this retrospective multicentric study of 238 patients followed almost 6 months after TC, participants were grouped based on if the TC decision was in accordance with the results of ITs conducted during the 3 months before TC, despite the results of ITs or without ITs done.

• Relapse occurred in 36 patients at 3 months post-TC: 14/95 of patients with TC in accordance with IT results (14.7%), 5/21 with TC despite ITs (23.8%) and 17/122 with TC without ITs (13.9%).

• The relapse rate 6 months post-TC were 18.9%, 28.6%, and 18.9%, respectively, in the 3 groups.